News
Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results